Production Lymphocyte Proliferation and Cytokine Tenascin-C Suppresses Activation-Induced T A 1 A 2 of the Extracellular Matrix Protein The Alternatively Spliced Domain TnFnIII
暂无分享,去创建一个
[1] P. Vielh,et al. Opposite regulation of tenascin-C and tenascin-X in MeLiM swine heritable cutaneous malignant melanoma. , 2000, Biochimica et biophysica acta.
[2] R. Chiquet‐Ehrismann,et al. Adhesion modulation by antiadhesive molecules of the extracellular matrix. , 2000, Experimental cell research.
[3] J. Schwarzbauer,et al. Tenascin-C Suppresses Rho Activation , 2000, The Journal of cell biology.
[4] P. Jones,et al. The tenascin family of ECM glycoproteins: Structure, function, and regulation during embryonic development and tissue remodeling , 2000, Developmental dynamics : an official publication of the American Association of Anatomists.
[5] S. Rosenberg. Identification of cancer antigens: impact on development of cancer immunotherapies. , 2000, Cancer journal.
[6] H. M. Geller,et al. Tenascin-C Contains Domains That Independently Regulate Neurite Outgrowth and Neurite Guidance , 1999, The Journal of Neuroscience.
[7] S. Schenk,et al. The fibrinogen globe of tenascin-C promotes basic fibroblast growth factor-induced endothelial cell elongation. , 1999, Molecular biology of the cell.
[8] D. Speiser,et al. Analysis of the cytolytic T lymphocyte response of melanoma patients to the naturally HLA-A*0201-associated tyrosinase peptide 368-376. , 1999, Cancer research.
[9] P. Möller,et al. Detection of tenascin‐C isoforms in colorectal mucosa, ulcerative colitis, carcinomas and liver metastases , 1999, International journal of cancer.
[10] C. Rüegg,et al. Tenascin‐C inhibits β1 integrin‐dependent T lymphocyte adhesion to fibronectin through the binding of its fnIII 1 – 5 repeats to fibronectin , 1999, European journal of immunology.
[11] K Schulten,et al. Forced unfolding of the fibronectin type III module reveals a tensile molecular recognition switch. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[12] H. M. Geller,et al. Neurite outgrowth promotion by the alternatively spliced region of tenascin-C is influenced by cell-type specific binding. , 1999, Matrix biology : journal of the International Society for Matrix Biology.
[13] P. Romero,et al. Diversity of the fine specificity displayed by HLA-A*0201-restricted CTL specific for the immunodominant Melan-A/MART-1 antigenic peptide. , 1998, Journal of immunology.
[14] N. Hiraiwa,et al. Effect of tenascin-C deficiency on chemically induced dermatitis in the mouse. , 1998, The Journal of investigative dermatology.
[15] D. Hanahan,et al. Tumor microenvironment can restrict the effectiveness of activated antitumor lymphocytes. , 1998, Cancer research.
[16] B. McIntyre,et al. Adenosine Diphosphate (ADP)-Ribosylation of the Guanosine Triphosphatase (GTPase) Rho in Resting Peripheral Blood Human T Lymphocytes Results in Pseudopodial Extension and the Inhibition of T Cell Activation , 1998, The Journal of experimental medicine.
[17] C. Geisler,et al. Two distinct pathways exist for down-regulation of the TCR. , 1998, Journal of immunology.
[18] Andres F. Oberhauser,et al. The molecular elasticity of the extracellular matrix protein tenascin , 1998, Nature.
[19] J. Clarke,et al. The effect of boundary selection on the stability and folding of the third fibronectin type III domain from human tenascin. , 1998, Biochemistry.
[20] N. Nakao,et al. Tenascin-C promotes healing of Habu-snake venom-induced glomerulonephritis: studies in knockout congenic mice and in culture. , 1998, The American journal of pathology.
[21] G. Phillips,et al. Domains of tenascin involved in glioma migration. , 1998, Journal of cell science.
[22] H. Erickson,et al. Mitogenic and adhesive effects of tenascin-C on human hematopoietic cells are mediated by various functional domains. , 1998, Matrix biology : journal of the International Society for Matrix Biology.
[23] P. Romero,et al. Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues. , 1998, Journal of immunology.
[24] G. Chaudhri,et al. Activation and signal transduction via mitogen‐activated protein (MAP) kinases in T lymphocytes , 1997, Immunology and cell biology.
[25] T. Boon,et al. Tumor antigens recognized by T lymphocytes , 1997, International journal of clinical & laboratory research.
[26] A. Markham,et al. Human tenascin‐C: Identification of a novel type III repeat in oral cancer and of novel splice variants in normal, malignant and reactive oral mucosae , 1997, International journal of cancer.
[27] T. Schulthess,et al. Concerted action of tenascin-C domains in cell adhesion, anti-adhesion and promotion of neurite outgrowth. , 1997, Journal of cell science.
[28] C. Rüegg,et al. Plasmin-induced proteolysis of tenascin-C: modulation by T lymphocyte-derived urokinase-type plasminogen activator and effect on T lymphocyte adhesion, activation, and cell clustering. , 1997, Journal of immunology.
[29] I. Campbell,et al. Rapid refolding of a proline-rich all-beta-sheet fibronectin type III module. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[30] S. Langdon,et al. Expression of the extracellular matrix protein tenascin in malignant and benign ovarian tumours. , 1996, British Journal of Cancer.
[31] D. Sheppard,et al. Differential Effects of the Integrins α9β1, αvβ3, and αvβ6 on Cell Proliferative Responses to Tenascin , 1996, The Journal of Biological Chemistry.
[32] Antonio Lanzavecchia,et al. T Cell Activation Determined by T Cell Receptor Number and Tunable Thresholds , 1996, Science.
[33] K. Crossin,et al. Tenascin: A multifunctional extracellular matrix protein with a restricted distribution in development and disease , 1996, Journal of cellular biochemistry.
[34] H. Erickson,et al. Mitogenesis, cell migration, and loss of focal adhesions induced by tenascin-C interacting with its cell surface receptor, annexin II. , 1996, Molecular biology of the cell.
[35] E. Spiess,et al. Tenascin-C contains distinct adhesive, anti-adhesive, and neurite outgrowth promoting sites for neurons , 1996, The Journal of cell biology.
[36] H. Erickson,et al. Binding of Tenascin-C to Soluble Fibronectin and Matrix Fibrils * , 1995, The Journal of Biological Chemistry.
[37] C. Rüegg,et al. Rapid increase in plasma tenascin‐C concentration after isolated limb perfusion with high‐dose tumor necrosis factor (TNF), interferon gamma (IFNγ) and melphalan for regionally advanced tumors , 1995, International journal of cancer.
[38] M. Bissell,et al. Tenascin-C inhibits extracellular matrix-dependent gene expression in mammary epithelial cells. Localization of active regions using recombinant tenascin fragments. , 1995, Journal of cell science.
[39] G. Vollmer,et al. Tenascin‐C in serum: an acute‐phase protein or a carcinoma marker? , 1995, International journal of cancer.
[40] Y. Okada,et al. Susceptibility of tenascin to degradation by matrix metalloproteinases and serine proteinases , 1994, FEBS letters.
[41] H. Erickson,et al. Cell surface annexin II is a high affinity receptor for the alternatively spliced segment of tenascin-C , 1994, The Journal of cell biology.
[42] K. Stefansson,et al. Inhibition of T cell activation by the extracellular matrix protein tenascin. , 1994, Journal of immunology.
[43] Dan R. Littman,et al. Signal transduction by lymphocyte antigen receptors , 1994, Cell.
[44] S. Beck,et al. Tenascin is a cytoadhesive extracellular matrix component of the human hematopoietic microenvironment , 1993, The Journal of cell biology.
[45] S. Hirohashi,et al. Constitutive expression of tenascin in T-dependent zones of human lymphoid tissues. , 1993, The American journal of pathology.
[46] H. Erickson,et al. Cell- and heparin-binding domains of the hexabrachion arm identified by tenascin expression proteins. , 1993, The Journal of biological chemistry.
[47] D. Longo,et al. Alterations in signal transduction molecules in T lymphocytes from tumor-bearing mice. , 1992, Science.
[48] Y. Soini,et al. Tenascin in reactive lymph nodes and in malignant lymphomas. , 1992, Pathology, research and practice.
[49] L. Zardi,et al. Expression of different tenascin isoforms in normal, hyperplastic and neoplastic human breast tissues , 1992, International journal of cancer.
[50] R. Tucker,et al. Tenascin in bone morphogenesis: expression by osteoblasts and cell type-specific expression of splice variants. , 1992, Journal of cell science.
[51] L. Zardi,et al. Comparison of human tenascin expression in normal, simian-virus-40-transformed and tumor-derived cell lines. , 1992, European journal of biochemistry.
[52] H. Erickson,et al. Focal adhesion integrity is downregulated by the alternatively spliced domain of human tenascin [published erratum appears in J Cell Biol 1992 Feb;116(3):833] , 1991, The Journal of cell biology.
[53] J. Gulcher,et al. Structure of the human hexabrachion (tenascin) gene. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[54] J. Gulcher,et al. The complete cDNA sequence of human hexabrachion (Tenascin). A multidomain protein containing unique epidermal growth factor repeats. , 1991, The Journal of biological chemistry.
[55] G. Casari,et al. Human tenascin: primary structure, pre-mRNA splicing patterns and localization of the epitopes recognized by two monoclonal antibodies. , 1991, Nucleic acids research.
[56] K. Horgan,et al. Costimulation of proliferative responses of resting CD4+ T cells by the interaction of VLA-4 and VLA-5 with fibronectin or VLA-6 with laminin. , 1990, Journal of immunology.
[57] J. Spring,et al. Two contrary functions of tenascin: Dissection of the active sites by recombinant tenascin fragments , 1989, Cell.
[58] C. Rüegg,et al. Tenascin, an extracellular matrix protein, exerts immunomodulatory activities. , 1989, Proceedings of the National Academy of Sciences of the United States of America.
[59] J. Gulcher,et al. An alternatively spliced region of the human hexabrachion contains a repeat of potential N-glycosylation sites. , 1989, Proceedings of the National Academy of Sciences of the United States of America.
[60] P. Ekblom,et al. Stimulation of tenascin expression in mesenchyme by epithelial-mesenchymal interactions. , 1989, The International journal of developmental biology.
[61] W. Halfter,et al. Induction of tenascin in healing wounds , 1988, The Journal of cell biology.
[62] S. Miescher,et al. Proliferative and cytolytic potentials of purified human tumor‐infiltrating t lymphocytes. Impaired response to mitogen‐driven stimulation despite T‐cell receptor expression , 1988, International journal of cancer.
[63] T. Espevik,et al. A highly sensitive cell line, WEHI 164 clone 13, for measuring cytotoxic factor/tumor necrosis factor from human monocytes. , 1986, Journal of immunological methods.
[64] M. Chiquet,et al. Chick myotendinous antigen. II. A novel extracellular glycoprotein complex consisting of large disulfide-linked subunits , 1984, The Journal of cell biology.
[65] P. Romero,et al. Frequent cytolytic T-cell responses to peptide MAGE-A10(254-262) in melanoma. , 2001, Cancer research.
[66] 俊 日比野. Tenascin Suppresses CD3-mediated T Cell Activation , 1998 .
[67] S. Constant,et al. Induction of Th1 and Th2 CD4+ T cell responses: the alternative approaches. , 1997, Annual review of immunology.
[68] M. Tan,et al. Expression of tenascin-C by human endometrial adenocarcinoma and stroma cells: heterogeneity of splice variants and induction by TGF-beta. , 1997, Biochemistry and cell biology = Biochimie et biologie cellulaire.
[69] H. Erickson,et al. Tenascin: an extracellular matrix protein prominent in specialized embryonic tissues and tumors. , 1989, Annual review of cell biology.
[70] M. Kripke. Immunologic mechanisms in UV radiation carcinogenesis. , 1981, Advances in cancer research.
[71] M. Bourdon,et al. Endothelial cell attachment and spreading on human tenascin is mediated by 2 1 and V 3 integrins , 2022 .